MILAN (MF-DJ) – With a national market for "primary care" drugs that will drop by 4.5% in 2012, with a forecast of an average annual drop of 4% in the next five years, Dompe' Farmaceutici is aiming at the new frontiers of biotech, namely Russia and the Far East.
A first clue, writes MF, is the agreement signed a few days ago with the Russian Chem Rar, a company that also works for the Federal Agency for Scientific Innovation, for the establishment of a joint venture aimed at developing and marketing a drug for the treatment of diabetes.
The company's goal now is to establish strategic partnerships also in Korea, China and Japan.
red/bc
(END) Dow Jones Newswires
November 02, 2012 04:11 ET (08:11 GMT)
